| Purdue Pharma L.P. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120123335 | TRANSDERMAL PATCH WITH ON-BOARD ENERGY STORAGE DEVICE - A transdermal patch can include a drug source, a porator, and an energy storage device on-board the patch. Conductive contact terminals can extend from the energy storage device for connection to an external source of power. The porator operates free of any concurrent connection to any external source of power. A switch can be used to make the selective electrical connection between the porator and the energy storage device. The switch can be arranged to respond to a manual user action after the patch has been adhered to skin, including separation of the porator from a remainder of the patch. Optionally, a series of switches can make electrical connections between the porator and respective individual energy storage devices. | 05-17-2012 |
| 20120116314 | TRANSDERMAL PATCH WITH PULL-TAB ACTUATED ENERGY STORAGE DEVICES - A transdermal patch can include a drug source, a porator, and an energy storage device on-board the patch. Conductive contact terminals can extend from the energy storage device for connection to an external source of power. The porator operates free of any concurrent connection to any external source of power. A switch can be used to make the selective electrical connection between the porator and the energy storage device. The switch can be arranged to respond to a manual user action after the patch has been adhered to skin, including separation of the porator from a remainder of the patch. Optionally, a series of switches can make electrical connections between the porator and respective individual energy storage devices. | 05-10-2012 |
| 20120116308 | TRANSDERMAL PATCH WITH PLURAL ON-BOARD ENERGY STORAGE DEVICES - A transdermal patch can include a drug source, a porator, and an energy storage device on-board the patch. Conductive contact terminals can extend from the energy storage device for connection to an external source of power. The porator operates free of any concurrent connection to any external source of power. A switch can be used to make the selective electrical connection between the porator and the energy storage device. The switch can be arranged to respond to a manual user action after the patch has been adhered to skin, including separation of the porator from a remainder of the patch. Optionally, a series of switches can make electrical connections between the porator and respective individual energy storage devices. | 05-10-2012 |
| 20120108622 | PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 05-03-2012 |
| 20120108621 | PHARMACEUTICAL PREPARATION CONTAINING OXYCODONE AND NALOXONE - The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner. | 05-03-2012 |
| 20120108575 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF - The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound. | 05-03-2012 |
| 20120095049 | NOCICEPTIN ANALOGS - A compound of the formula (I), (II), (III) or (IV) | 04-19-2012 |
| 20120022259 | METHODS FOR MAKING 3-O-PROTECTED MORPHINONES AND 3-O-PROTECTED MORPHINONE DIENOL CARBOXYLATES - Disclosed are methods for making aldehydes and ketones comprising allowing the corresponding primary or secondary alcohol to react in the presence of trichoroisocyanuric acid, a compound of formula R | 01-26-2012 |
| 20120015954 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 01-19-2012 |
| 20120004941 | CYCLE PLANNING TOOL WITH EVENT CONFLICT RESOLUTION FOR TERRITORY MANAGEMENT - Electronically creating a schedule plan of events which replicates one or more previously scheduled events. A source date range is acquired into a memory of a machine A set of previously scheduled events within the source date range is identified. A target date range is received through a user interface. At least a portion of the previously scheduled events is assigned to a date within the received target date range to create the schedule plan. The schedule plan is posted to a calendar. Another method creates a schedule plan on the basis of one or more search criteria used for identifying any match from a database. At least a portion of any matches are assigned a time slot within a target date range of a calendar program. | 01-05-2012 |
| 20120004217 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 01-05-2012 |
| 20110288100 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses a compound of formula: | 11-24-2011 |
| 20110281885 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 11-17-2011 |
| 20110281876 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses compounds of formula: | 11-17-2011 |
| 20110262532 | Controlled Release Hydrocodone Formulations - A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C | 10-27-2011 |
| 20110256226 | OPIOID AGONIST FORMULATIONS WITH RELEASABLE AND SEQUESTERED ANTAGONIST - Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof. | 10-20-2011 |
| 20110217243 | PHARMACEUTICAL IDENTIFICATION - Disclosed are methods for marking a pharmaceutical product, container or pharmaceutical packaging system with a scent to establish the identity and/or source of the pharmaceutical. | 09-08-2011 |
| 20110207762 | OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE - In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. | 08-25-2011 |
| 20110152324 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 06-23-2011 |
| 20110136846 | Buprenorphine Analogs - The present invention is directed to Buprenorphine Analog compounds of the Formula I, Formula II or Formula III shown below, wherein R | 06-09-2011 |
| 20110104214 | ONCE-A-DAY OXYCODONE FORMULATIONS - The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C | 05-05-2011 |
| 20110098281 | Benzenesulfonyl Compounds and the Use Thereof - The invention relates to pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 04-28-2011 |
| 20110097404 | TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS - Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact. | 04-28-2011 |
| 20110082152 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 04-07-2011 |
| 20110071192 | Therapeutic Agents Useful for Treating Pain - A compound of formula: | 03-24-2011 |
| 20110038927 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 02-17-2011 |
| 20110009418 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses compounds of formula: | 01-13-2011 |
| 20110002975 | PREOPERATIVE TREATMENT OF POST OPERATIVE PAIN - A method of treating postoperative pain in a patient undergoing a surgery is described. The method is based on preoperative administration of a buprenorphine-containing transdermal dosage form. The dosage form can be administered to the patient, for example, 1-4 days prior to surgery. Alternative embodiments of the invention include subsequent transdermal dosage forms to treat the postoperative pain. | 01-06-2011 |
| 20100331369 | Therapeutic Agents Useful for Treating Pain - A compound of formula: | 12-30-2010 |
| 20100324080 | Benzomorphan Compounds - The invention relates to Benzomorphan Compounds of Formula (I): wherein X, R | 12-23-2010 |
| 20100317670 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - The present invention discloses a compound of formula: | 12-16-2010 |
| 20100291203 | Opioid Agonist/Antagonist Combinations - The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome). | 11-18-2010 |
| 20100261713 | PHARMACEUTICAL FORMULATION CONTAINING IRRITANT - Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering. | 10-14-2010 |
| 20100240675 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - Compounds of formulae: | 09-23-2010 |
| 20100234426 | Phenylpropionamide Compounds and the Use Thereof - The invention relates to phenylpropionamide compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A, B, R | 09-16-2010 |
| 20100216726 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof - The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound. | 08-26-2010 |
| 20100210686 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - Piperidine Compounds; compositions comprising a Piperidine Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperidine Compound are disclosed. In one embodiment, the Piperidine Compound has the formula: | 08-19-2010 |
| 20100152449 | 8a,14-DIHYDROXY-7,8-DIHYDROCODEINONE - In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. | 06-17-2010 |
| 20100092570 | CONTROLLED RELEASE OXYCODONE COMPOSITIONS - A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed. | 04-15-2010 |
| 20100069437 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - 4-Tetrazolyl-4-phenylpiperidine Compounds, compositions comprising an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound, methods for treating or preventing pain or diarrhea in an animal comprising administering to an animal in need thereof an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound and methods for stimulating opioid-receptor function in a cell comprising contacting a cell capable of expressing an opioid receptor with an effective amount of a 4-Tetrazolyl-4-phenylpiperidine Compound are disclosed. | 03-18-2010 |
| 20100063030 | Benzenesulfonyl Compounds and the Use Thereof - The invention relates to pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 03-11-2010 |
| 20100034876 | CONTROLLED RELEASE OXYCODONE COMPOSITIONS - A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients by administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone or a salt thereof, such that a mean maximum plasma concentration of oxycodone up to about 240 ng/ml from a mean of up to about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration up to about 120 ng/ml from about 10 to about 14 hours after repeated “q12h” (i.e., every 12 hour) administration through steady-state conditions are achieved. Controlled release oxycodone formulations for achieving the above are also disclosed. | 02-11-2010 |
| 20100022595 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels - The invention relates to piperidinyl and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 01-28-2010 |
| 20100022439 | Nanostructures with High Load of Active Agents - The present invention provides an improved method of loading silica nanostructures with an active agent, comprising exposing a mixture comprising a liquid medium containing an active agent and silica nanostructures to reduced air pressure for a time period, and then returning the mixture to atmospheric air pressure at the end of the time period. | 01-28-2010 |
| 20100004254 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 01-07-2010 |
| 20090291947 | PROLINE ANALOGS AS LIGANDS FOR CANNABINOID RECEPTORS - The present invention relates to Proline Analog Compounds that are ligands for cannabinoid receptors, compositions comprising a Proline Analog Compound and a pharmaceutically-acceptable carrier, methods of making such Proline Analog Compounds, and methods for treating or preventing a Condition comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof. | 11-26-2009 |
| 20090253727 | NOCICEPTIN ANALOGS - A compound of the having the general formula (I) or general formula (II): | 10-08-2009 |
| 20090202629 | Controlled release hydrocodone formulations - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 08-13-2009 |
| 20090176838 | Cyclourea Compounds as Calcium Channel Blockers - The invention relates to cyclourea compounds of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R | 07-09-2009 |
| 20090083334 | SYSTEM AND METHODS FOR MANAGEMENT OF RISK DATA AND ANALYTICS - Managing and analyzing occurrences of certain types of adverse events associated with a distribution of a prescription drug into the commercial marketplace, such as a drug having an associated abuse liability potential. Data concerning an occurrence of an adverse event associated with such distribution is received and selectively logged as an event if the data satisfies one or more predetermined criteria which can be used to filter the received data. If the received data are logged as an event, a score is computed and assigned to the event. If the score meets or exceeds a pre-established threshold, a field researcher is assigned to investigate the logged event. Further data from the field researcher are stored in association with the logged event. Automated review of further data from field researchers can be performed to update the status of a logged event to closed. | 03-26-2009 |
| 20090081290 | TAMPER RESISTANT DOSAGE FORMS - The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof. | 03-26-2009 |
| 20090081287 | Pharmaceutical Composition Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 03-26-2009 |
| 20090081200 | Tissue Factor Antibodies and Uses Thereof - The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention. | 03-26-2009 |
| 20090068269 | ORALLY ADMINSTRABLE OPIOID FORMULATIONS HAVING EXTENDED DURATION OF EFFECT - Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm. | 03-12-2009 |
| 20090042902 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN - A compound of formula: | 02-12-2009 |
| 20090008401 | Dispenser with Corner Latches - A dispenser having a storage compartment may hold a blister package or other object. The blister package may be slid in and out of the dispenser through an opening. Corner latches pivotally attached to the dispenser on either side of the opening move between a first position and a second position. In the first position, a portion of the corner latches extend into the opening thereby preventing the object from being removed from the dispenser. The corner latches are moved to the second position such that the corner latches no longer block the opening to the dispenser so that the blister package may be removed. | 01-08-2009 |
| 20090008286 | Dispenser with a Spout - A dispenser with a spout holds a plurality of objects, such as pharmaceutical dosage forms. The dispenser has a housing defining an interior space that holds the pharmaceutical products and an opening leading to the interior space. A movable spout is disposed in the opening and is able to pivot between a closed position wherein the opening is occluded, or sufficiently occluded, by the spout thereby preventing objects disposed within the interior space from exiting the housing through the opening and an open position wherein the opening is not occluded, or sufficiently unoccluded, by the spout thereby permitting objects disposed within the interior space to exit the housing through the opening. The dispenser also has an opener with a push button for moving the spout from the closed position to the open position about the pivot axis when pressure is applied to the opener wherein the opener engages one end of the spout below the pivot axis to push another end of the spout outward from the housing. | 01-08-2009 |
| 20080318932 | Sodium Channel Blocker Compositions and the Use Thereof - Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are pharmaceutical compositions and kits for the treatment or prevention of chronic pain or convulsion. | 12-25-2008 |
| 20080311199 | TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS - Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers. | 12-18-2008 |
| 20080311198 | TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS - Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers. | 12-18-2008 |
| 20080306104 | TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS - Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers. | 12-11-2008 |
| 20080305167 | TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS - Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers. | 12-11-2008 |
| 20080300902 | METHOD OF IDENTIFYING LOCATIONS EXPERIENCING ELEVATED LEVELS OF ABUSE OF OPIOID ANALGESIC DRUGS - In the field of pharmacovigilance (monitoring of adverse events associated with the use of marketed prescription drugs), an improved method of detecting “signals” of abuse or diversion of pharmaceuticals is needed, in order to more reliably distinguish real anomalies in pharmaceutical consumption in particular locations from apparent anomalies which are statistical artifacts of high local concentrations of authorized pharmaceutical users. An improved method relies upon government statistics on adverse drug reactions and on census statistics, and employs a Poisson statistical model to adjust for both fixed effects and random effects, such as spatial relations between different locations. The more accurate “signals” provided by the improved method permit public health and law enforcement officials to allocate public resources more efficiently and effectively. | 12-04-2008 |
| 20080292694 | Opioid agonist/antagonist combinations - The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome). | 11-27-2008 |
| 20080281858 | ITINERARY SEARCH TOOL FOR TERRITORY MANAGEMENT - Electronically creating an itinerary schedule in a calendar program. A geographic indicator and a calendar date are acquired and coordinated with each other to define an itinerary entry. The itinerary entry is included into a calendar program maintained by the machine. The step of acquiring the geographic indicator further comprises the step of updating a counter upon each selection of a geographic indicator. Another method electronically populates a calendar program with an event using an itinerary entry. Optionally, health care providers from within a geographic indicator are included in the itinerary entry. A geographic indicator and calendar date are obtained from an itinerary entry, and additional search criteria are input. A search of a database is executed to identify candidates matching the geographic indicator and search criteria. Candidate matches are assigned to a time slot, and each time slot is populated into the calendar program on the calendar date. | 11-13-2008 |
| 20080262284 | DISPOSAL SYSTEM FOR TRANSDERMAL DOSAGE FORM - The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. | 10-23-2008 |
